282 related articles for article (PubMed ID: 22681512)
1. Sativex® in multiple sclerosis spasticity: a cost-effectiveness model.
Slof J; Gras A
Expert Rev Pharmacoecon Outcomes Res; 2012 Aug; 12(4):439-41. PubMed ID: 22681512
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of Sativex in multiple sclerosis spasticity: new data and application to Italy.
Slof J; Ruiz L; Vila C
Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):379-91. PubMed ID: 25771713
[TBL] [Abstract][Full Text] [Related]
3. A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany.
Flachenecker P
Expert Rev Neurother; 2013 Feb; 13(3 Suppl 1):15-9. PubMed ID: 23369055
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of oromucosal cannabis-based medicine (Sativex®) for spasticity in multiple sclerosis.
Lu L; Pearce H; Roome C; Shearer J; Lang IA; Stein K
Pharmacoeconomics; 2012 Dec; 30(12):1157-71. PubMed ID: 23072659
[TBL] [Abstract][Full Text] [Related]
5. Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.
Vermersch P
Expert Rev Neurother; 2011 Apr; 11(4 Suppl):15-9. PubMed ID: 21449855
[TBL] [Abstract][Full Text] [Related]
6. A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis.
Gras A; Broughton J
Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):771-779. PubMed ID: 26750641
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity.
Oreja-Guevara C
Expert Rev Neurother; 2012 Apr; 12(4 Suppl):3-8. PubMed ID: 22509985
[TBL] [Abstract][Full Text] [Related]
8. THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.
Sastre-Garriga J; Vila C; Clissold S; Montalban X
Expert Rev Neurother; 2011 May; 11(5):627-37. PubMed ID: 21456949
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis.
Mantovani LG; Cozzolino P; Cortesi PA; Patti F;
Clin Drug Investig; 2020 Apr; 40(4):319-326. PubMed ID: 32130684
[TBL] [Abstract][Full Text] [Related]
10. Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice.
Pozzilli C
Expert Rev Neurother; 2013 Dec; 13(12 Suppl):49-54. PubMed ID: 24289844
[TBL] [Abstract][Full Text] [Related]
11. Drug-resistant MS spasticity treatment with Sativex(®) add-on and driving ability.
Freidel M; Tiel-Wilck K; Schreiber H; Prechtl A; Essner U; Lang M
Acta Neurol Scand; 2015 Jan; 131(1):9-16. PubMed ID: 25208898
[TBL] [Abstract][Full Text] [Related]
12. Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain.
García-Merino A
Expert Rev Neurother; 2013 Feb; 13(3 Suppl 1):9-13. PubMed ID: 23369054
[TBL] [Abstract][Full Text] [Related]
13. Cortical and spinal excitability in patients with multiple sclerosis and spasticity after oromucosal cannabinoid spray.
Squintani G; Donato F; Turri M; Deotto L; Teatini F; Moretto G; Erro R
J Neurol Sci; 2016 Nov; 370():263-268. PubMed ID: 27772772
[TBL] [Abstract][Full Text] [Related]
14. What place for ▾ cannabis extract in MS?
Drug Ther Bull; 2012 Dec; 50(12):141-4. PubMed ID: 23241565
[TBL] [Abstract][Full Text] [Related]
15. Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice--results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity.
Flachenecker P; Henze T; Zettl UK
Eur Neurol; 2014; 71(5-6):271-9. PubMed ID: 24525548
[TBL] [Abstract][Full Text] [Related]
16. Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis.
Meuth SG; Vila C; Dechant KL
Expert Rev Neurother; 2015; 15(8):909-18. PubMed ID: 26166264
[TBL] [Abstract][Full Text] [Related]
17. Impact of Sativex(®) on quality of life and activities of daily living in patients with multiple sclerosis spasticity.
Arroyo R; Vila C; Dechant KL
J Comp Eff Res; 2014 Jul; 3(4):435-44. PubMed ID: 25275238
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis.
Moreno Torres I; Sanchez AJ; Garcia-Merino A
Expert Rev Neurother; 2014 Nov; 14(11):1243-50. PubMed ID: 25331416
[TBL] [Abstract][Full Text] [Related]
19. Clinical case reviews in multiple sclerosis spasticity: experiences from around Europe.
Koehler J; Amato MP; Oreja-Guevara C; Lycke J
Expert Rev Neurother; 2013 Dec; 13(12 Suppl):61-6. PubMed ID: 24289846
[TBL] [Abstract][Full Text] [Related]
20. Advances in the management of multiple sclerosis spasticity: recent clinical trials.
Fernández O
Eur Neurol; 2014; 72 Suppl 1():9-11. PubMed ID: 25278117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
